Financial Data and Key Metrics Changes - The company reported net income of $0.52 per diluted share for Q4 2025, an increase from $0.43 in Q4 2024, driven by unrealized gains on preferred stock and stock warrant investments [4] - Earnings available for distribution (EAD) was $0.48 per diluted share, down from $0.83 in Q4 2024, while cash available for distribution (CAD) increased to $0.53 per diluted share from $0.47 in the prior quarter [4] - For the full year, net income was $2.09 per diluted share, more than double the $1.02 reported in 2024, primarily due to higher net interest income [6] - Interest income rose by $17.4 million to $89.9 million for 2025, while interest expense decreased from $44.4 million to $42.8 million [6] Business Line Data and Key Metrics Changes - The portfolio consists of 92 investments with a total outstanding balance of $1.2 billion, allocated as follows: 47% multifamily, 30% life sciences, 17% single-family rental, and the remainder across storage, marina, and industrial [7] - The collateral on the portfolio is 82.5% stabilized, with a loan-to-value ratio of 63.6% and a weighted average debt service coverage ratio of 1.24 times [8] - The NexPoint storage portfolio finished 2025 at 91.7% occupancy, exceeding its NOI budget by 3.2% and growing NOI by 13% over 2024 [19] Market Data and Key Metrics Changes - Geographically, collateral is concentrated in Massachusetts (24%), Texas (16%), and California (7%), with significant exposure to life sciences in Massachusetts and California [7] - The self-storage industry is facing occupancy pressure, with the average ending 2025 at 89%, down 210 basis points from the start of the year [18] Company Strategy and Development Direction - The company is focused on recession-resilient property types such as residential and self-storage, avoiding investments in AI scare trade assets [11] - The company is optimistic about the multifamily sector, expecting positive rent inflection in the second half of 2026 due to structural demand and a decline in new market rate deliveries [16] - The company is actively pursuing opportunities in build-to-rent assets, with a pipeline consisting of various investments across multifamily, life sciences, and self-storage [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in dividend sustainability, noting that cash available for distribution is a better indicator of coverage than earnings available for distribution [27] - The company anticipates that the demand for life sciences and residential properties will continue to grow, driven by demographic trends and advancements in health and wellness [16][42] - Management believes that the regulatory environment will create opportunities in the build-to-rent sector, particularly if institutional buyers face limitations [32] Other Important Information - The company raised $60.5 million in gross proceeds from a Series B preferred stock offering and launched a Series C preferred stock at 8% [5][9] - The company refinanced $36.5 million in unsecured notes with a new $45 million offering at 7.875%, positioning itself well in a declining interest rate environment [9] Q&A Session Summary Question: Dividend sustainability and confidence in current level - Management noted that EAD is slightly below CAD, but CAD is viewed as a better indicator for dividend coverage, and they feel well-positioned for future sustainability [27][28] Question: Areas of portfolio excitement and impact of regulations - Management is focused on life sciences and build-to-rent assets, believing there are significant opportunities in these sectors despite potential regulatory changes [31][32] Question: Provision for credit loss and future expectations - Management indicated that the recent provision for credit loss was conservative and expects it to level off in 2026 [38] Question: Characteristics driving positive performance in life science projects - The Alyfe Park project is purpose-built and well-located, which has driven leasing activity despite challenging market dynamics [40][41] Question: Details on loans made in the quarter - Management provided details on loans, including a $22.5 million loan at 11% and emphasized a focused approach to investment selection [48]

Exelixis FY Conference Summary Company Overview - Exelixis is a commercial-stage biotech company focused on oncology, primarily known for its lead product, CABOMETYX (cabozantinib), which targets VEGFR and has been on the market for over 10 years with multiple indications [6][7] Key Insights Product Performance - CABOMETYX has shown strong revenue growth, with a notable expansion into neuroendocrine tumors (NET) that began at the end of Q1 2025 [6][16] - The oral therapy market for NET is estimated to be around $1 billion, with Exelixis aiming to capture a significant share [17] - In Q2 2025, CABOMETYX accounted for approximately 4% of Exelixis' business, translating to about $20 million in revenue [18][19] Market Strategy - The company is focused on differentiating its products in a competitive landscape, emphasizing the need for innovative therapies rather than "me too" drugs [7] - Exelixis is exploring opportunities in China, recognizing the potential for collaboration and innovation in the biopharma ecosystem [9][10] Regulatory Environment - Regulatory challenges, particularly related to chargebacks and government policies, are significant concerns for the industry, impacting R&D funding and patient care [13][14] Pipeline Development - Zanza, a third-generation VEGFR targeting TKI, is being developed to improve upon CABOMETYX, particularly in terms of dosing flexibility due to its shorter half-life [23][24] - Exelixis is prioritizing its pipeline based on competitive profiles and potential market opportunities, with a focus on indications like colorectal cancer and meningioma [45][46] Financial Performance - The company has maintained a disciplined approach to capital allocation, generating approximately $1.8 billion in buybacks since mid-2023 and remaining profitable for several consecutive quarters [58][59] - Exelixis aims to cap R&D spending at about $1 billion annually while balancing investments in business development and shareholder returns [57][59] Additional Considerations - The company is cautious about the use of AI in R&D, focusing on practical applications rather than over-investing in unproven technologies [11][12] - Exelixis is committed to building a robust pipeline of franchise molecules, with the goal of developing multiple successful products in rapid succession [22][52] - The competitive landscape for therapies in the MCLC space is evolving, with Exelixis positioning Zanza as a strong contender against existing treatments [33][34] Conclusion - Exelixis is strategically navigating the oncology market with a focus on innovative therapies, regulatory challenges, and disciplined financial management, while actively developing its pipeline to ensure long-term growth and shareholder value [6][57][58]